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still present for the patients that were under therapy after 42 months.
All scores obtained at followup visits showed statistical signiﬁcance
(p< 0.001) when compared with scores obtained at baseline.
Conclusions: Our data suggest that hip viscosupplementation may be
an effective and cost-saving treatment for both patients and Healthcare
system, not only because the spending for NSAID is lowered (direct
costs), but also because gastrointestinal and cardiovascular side effects
commonly associated with NSAID may be reduced (indirect costs).
539 THE EFFECT OF TETRACYCLINES ON HUMAN ARTICULAR
CARTILAGE METABOLISM ARE DEPENDENT ON THE
DEGREE OF OSTEOARTHRITIC ALTERATIONS
J. Steinmeyer, J. Kordelle. Orthopaedic Research Laboratories, Dept.
of Orthopaedic Surgery, University Hospital Giessen and Marburg,
Giessen, GERMANY
Purpose: In search for potential new therapies in the treatment of
osteoarthritis (OA), attention has focused also on tetracyclines and their
ability to slow down the progression of OA. Several possible mechanisms
have been proposed, including inhibition of the activity and expression
of inducible nitric oxide synthase (iNOS) and matrix metalloproteinases
(MMPs). Using normal bovine articular cartilage, minocycline were found
to have a stronger inhibitory effect on e.g. the expression of iNOS and
MMP-1 than doxycycline.
In this line, the purpose of this in vitro study was to determine system-
atically whether tetracyclines (1) inﬂuences the synthesis and release of
PGs, MMPs and PGE2 also from human OA cartilage, (2) are affected by
the degree of OA alterations, (3) are different with respect to their individ-
ual ability to modulate cartilage metabolism, and (4) affect chondrocyte
viability within human OA cartilage explants.
Methods: Full-thickness cartilage explants of the lateral compartment of
the femoral condyles were taken from OA patients undergoing knee re-
placement surgery. 4-mm-diameter articular cartilage discs were obtained
using a biopsy punch. The degree of OA changes of the femoral condyles
was determined according to Collins. Explants from mild (Collins grade
0−1.5) or moderately (Collins grade >1.5−3) affected human OA condyles
were cultured separately in supplemented Ham’s F12 media with media
changes every 3−4 days. Explants were treated with 1, 10, 50 or 100 mM
minocycline, doxycycline or tetracycline in the presence or absence of rec.
human Il-1b (5 ng/ml). PG synthesis was determined by the incorporation
of 35SO4 during the ﬁnal 18 h of the 11 days experiments whereas the
content of PGs were quantitated with the DMMB-assay. The viability of
chondrocytes was assessed microscopically using ﬂuorescein diacetate
and propidium iodide. Nitrite levels in media were measured by using the
Griess reaction. MMP-1, -8, and -13 as well as PGE2 were determined
in media with ELISAs. Results were compared to untreated explants
removed from the same joint. Each experimental condition was repeated
ﬁve times using explants always obtained from 6 different patients (N=6).
Results: The degree of OA alterations of explants can have a profound
modulatory effect on the inﬂuence of tetracylines on cartilage metabolism.
Furthermore, doxycycline partly displayed a weaker pharmacological
effect than minocycline, whereas tetracycline was found to have the
lowest potential to change cartilage metabolism. The viability of explants
was not affected by any of the drugs tested.
Conclusions: Our study indicate that the pharmacological efﬁcacy of
tetracyclines can be dependent on the clinical stage of OA. In addition,
our ﬁndings indicate that minocycline possess a stronger potential than
doxycycline to slow down cartilage destruction during OA.
540 FUNCTIONAL AND STRUCTURAL IMPROVEMENTS IN
A DOG ANTERIOR CRUCIATE LIGAMENT MODEL:
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Purpose: To investigate the efﬁcacy of the anabolic agent ﬁbroblast
growth factor 18 (rhFGF18; AS902330) in counteracting structural dam-
age and functional impairment in a dog anterior cruciate ligament (ACL)
model of osteoarthritis (OA) over 26 weeks.
Methods: From week 4 after surgical section of the right ACL in mongrel
dogs, intra-articular injections of AS902330 3mg, 10mg or 30mg per joint
(n = 8/dose group) or placebo (saline; n = 8) were given into the OA knee
once a week for 3 consecutive weeks. The animals were followed up
through week 26. Peak vertical force (PVF) was recorded at baseline
and at weeks 4, 8, 14, 20 and 26. MRI of the stiﬂe joint was performed
at weeks 4, 8 and 26. Semi-quantitative scores were determined for
osteophytosis, bone marrow lesions and cartilage defects, and cartilage
volume was measured. Macroscopic measurements of cartilage lesions
(condyles and plateaus) were performed at weeks 8 (3 dogs/group) and
26 (5 dogs/group). Exposure was determined using high performance
ELISA. All injections were undertaken and evaluations performed by
investigators blinded to the assigned treatment.
Results: Following section of the ACL, all dogs developed functional
impairment, but there was less loss of PVF in dogs treated with any of
the tested doses of AS902330 than in controls. In placebo-treated dogs,
the evolution of structural damage over time (weeks 4−26) correlated
with worsening limb function as expressed by PVF. As early as week 8
(i.e. at the end of intra-articular therapy), differences in joint functionality
could be detected between AS902330-treated dogs and placebo-treated
dogs. At week 8, mean PVF loss in the AS902330-treated group given
30mg/joint was 36.3% of baseline values, versus 47.8% in controls
(p =0.082; Mann-Whitney U test). A signiﬁcant difference in PVF loss
was also seen between AS902330 30mg and saline at week 14 (26.2%
vs 44.4%, p =0.007). The difference between groups (AS902330 30 mg
vs saline) was less pronounced at weeks 20 and 26 (35.2% vs 38.5%;
23.9% vs 33.5%, respectively). Measures of contact area followed a
similar pattern to PVF. Macroscopic gross pathology and microscopic
evaluation of cartilage using the International Cartilage Repair Society
scoring system revealed a clear reduction in the severity of cartilage
lesions in AS902330-treated dogs compared with controls at the end of
therapy (8 weeks) and after longer term follow-up (26 weeks). In addi-
tion, immunostaining for catabolic factors (e.g. matrix metalloproteinases,
inducible nitric oxide synthase) revealed a reduction in staining in the
cartilage of AS902330-treated dogs, which was maintained up to the end
of the study period (26 weeks). Systemic exposure after intra-articular
administration of AS902330 was below the lower limit of quantiﬁcation
(50 pg/mL).
Conclusions: Intra-articular injection with the anabolic agent AS902330
was shown to reduce progression of structural damage and alleviate limb
impairment in an ACL model of OA in dogs. The reduction in catabolic
parameters in the OA joint of treated animals, improved histopathology
scoring, and the improved functionality compared with saline-treated con-
trols support the hypothesis that treatment with rhFGF18 may inﬂuence
the course of OA and reduce functional impairment.
541 HCT 1026, A CYCLOOXYGENASE-INHIBITING NITRIC
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Purpose: Osteoarthritis (OA) and rheumatoid arthritis are characterized
by a reduction of extracellular matrix and increased catabolism of colla-
gen ﬁbers and glycosaminoglycans in joints. Conventional therapy with
traditional non steroidal anti-inﬂammatory drugs (NSAIDs) and selective
COX-2 inhibitors may increase progression of cartilage degradation,
especially in long-term treatments (Mastbergen, Arthritis Res Ther 2006).
The role of nitric oxide (NO) in OA is still controversial, since it has
been recognized as a marker of inﬂammation and a possible cause
of chondrocyte loss, but also as a potent immuno-modulating factor
improving joint vascular perfusion (Hancock & Riegger-Krugh, Clin J Pain
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2008). Cyclooxygenase-Inhibiting Nitric Oxide Donators (CINODs) are a
new class of anti-arthritic drugs, which inhibit in a balanced way both
COX-1 and COX-2 while releasing nitric oxide, an important modulator of
vascular tone. We present here the effects of HCT 1026, a ﬂurbiprofen-
based CINOD, on chondrocytes, focusing on their catabolic and anabolic
activities, as well as activation of inﬂammatory pathways.
Methods: Isolated primary cultures of bovine and human articular chon-
drocytes (BAC and HAC) were preincubated with 10mM HCT 1026 or
ﬂurbiprofen and stimulated with Il-1b, in hypoxic or normoxic conditions.
Levels of mRNA for extracellular matrix proteins (aggrecan and collagen
type II) and matrix metalloproteases (MMPs), as well as TGFb receptor,
were determined by quantitative RT-PCR. NO release was assessed
on cell supernatants through the Griess reaction, and activities of NF-
úB and AP-1 were determined by electrophoretic mobility shift assay.
NO donation from HCT 1026 was evaluated by testing its vasorelaxing
activity in norepinephrine-precontracted rabbit aortic rings, in presence
or absence of 10 mM ODQ (a speciﬁc inhibitor of NO-dependent cGMP
formation).
Results: In hypoxic human articular chondrocytes stimulated with Il-1b,
both HCT 1026 and ﬂurbiprofen decreased expression of MMP-1 and -3
and TGF-b receptor by 20 to 40%. However, only HCT 1026 inhibited
Il-1b-dependent NO overproduction while did not affect basal aggrecan
or type II collagen mRNAs. Moreover, in BAC cultured in normoxic
conditions, HCT 1026 inhibited NF-úB and AP-1 activation, whereas
ﬂurbirprofen affected only AP-1 activity. HCT 1026, but not ﬂurbiprofen,
induced aorta vasorelaxation, with an EC50 of 5.9±1.2mM. ODQ pretreat-
ment abolished this effect, conﬁrming that vascular relaxation by HCT
1026 was based on its NO donating properties.
Conclusions: The CINOD HCT 1026 modulates chondrocytes catabolic
and anabolic metabolism, causing reduction of inﬂammatory markers
such as NO biosynthesis and activation of NF-úB. Moreover, HCT 1026
is able to donate biologically relevant nitric oxide, which can modulate
vascular tone. If conﬁrmed in in vivo studies, our data may provide
evidence that the ability of CINODs to donate NO have a potential
beneﬁcial impact on joint cartilage in OA patients.
542 EFFECTIVENESS OF MELOXICAM FOR TREATMENT OF
PAIN SYNDROME UNDER KNEE OSTEOARTHRITIS, LOW
BACK PAIN AND NECK PAIN IN ELDERLY PEOPLE
V.V. Povoroznyuk, M.A. Bystrytska, T.V. Orlyk. Institute of Gerontology
AMS Ukraine, Kiev, UKRAINE
Purpose: The research was aimed at evaluating of the effectiveness
of meloxicam (revmoxicam) for treatment of pain syndrome under knee
osteoarthritis, low back pain and neck pain in elderly people.
Methods: The patients were devided into three groups. The ﬁrst group
included 11 patients (aged 61.1±5.54 years) with neck pain, the second
group included 10 patients (aged 59.4±4.65 years) with low back pain and
the third group included 10 patients (aged 57.9±7.5 years) with knee os-
teoarthritis. All patients took meloxicam 15mg once per day during 5 days.
The following methods of study were used: Mc-Gill questionnaire, VAS,
WOMAC, determination of life quality by Roland-Morris questionnaire,
Neck disability index, EuroQol 5D scale.
Table 1. Dynamics of pain syndrome intensive after meloxicam treatment in patient of different
groups.
Index Group Before
treatment
After 5 days
of treatment
P Two weeks without
treatment
P
Index of pain, cm I 444±0.71 4.11±0.78 0.35 3.22±3.00 0.01
II 5.13±0.59 4.13±0.79 0.03 3.63±0.52 0.003
III 5.98±2.22 3.56±1.74 0.001 3.66±1.86 0.043
Descriptors, ball I 9.56±2.23 7.56±2.40 0.09 7.56±1.71 0.12
II 11.0±2.29 8.63±2.79 0.016 9.63±3.65 0.49
III 10.60±4.70 7.40±4.80 0.008 8.70±6.00 0.043
Ranks, ball I 18.78±5.17 13.22±5.28 0.07 12.00±3.52 0.03
II 23.50±6.71 16.88±6.61 0.006 18.88±8.06 0.36
III 23.30±16.10 16.50±11.70 0.01 18.50±15.0 0.57
Results: After 5 days of treatment patients, who was taking meloxicam,
noticed a signiﬁcant decrease of pain syndrome and it became low after
two weeks without treatment [Table].
Signiﬁcant decrease of all parameters of pain syndrome in second and
third groups was observed after 5 days. Intensity of pain syndrome was
also certainly decreased after two weeks without treatment in all groups
by some parameters. The difference of effectiveness of meloxicam in
patient with different diseases was observed by VAS: decrease of pain
syndrome in the ﬁrst group was – 7%, in the second groups – 17%,
and in the third group – 39%, F=2.76, p = 0.08. During the period of
research no patients who undergone treatment had registered any side
effects. There was no signiﬁcant difference between groups dealing with
the improvement of patient’s everyday activity.
Conclusions: It can be concluded that the meloxicam is effective and
safe in the treatment of low back pain syndrome, neck pain syndrome
and pain syndrome under knee osteoarthritis in elderly people. However,
the best effect of meloxicam was observed in patients with pain syndrome
under knee osteoarthritis that can be explained by the inﬂammatory
component of osteoarthritis pathogenesis.
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Purpose: The research was aimed at evaluating the effectiveness of two
regimes (continuous and interrupted) of Theraﬂex (500mg glucosamine
hydrochloride, 400mg chondroitin sulphate) in patients with knee os-
teoarthritis. Outcomes evaluated were pain, measures of performance
(function, activity of daily living, disability), employment status, range of
motion, and patient satisfaction/patient global perceived effects.
Methods: The ﬁrst group included 50 patients (aged 64.5±1.1 years)
with knee osteoarthritis (II stage, Kellgren-Lawrence’s classiﬁcation), who
took the drug in continuous regime during 9 months. The second group
included 50 patients with the same diagnosis (aged 64.6±1.0 years),
who took Theraﬂex twice during 3 months with 3 months interruption.
We examined the patients before the treatment and after 1, 3, 6, 9 and
12 months. Methods of study: Mc-Gill questionnaire, visual-analogical
scale (VAS), Lequen’s index, WOMAC, EuroQol-5D, 15-m. test, 6-min.
test.
Results: After three months of Theraﬂex’s treatment it was observed a
reliable decrease of pain syndrome in both groups by WOMAC, decrease
of constraint in movements, improvement of index of everyday activity,
VAS, 15-m.test. Examination of patients during 6, 9 and 12 months
show the effectiveness of both regimes of the therapy. Intensity of pain
syndrome and functional activity didn’t differ between the groups.
Conclusions: During 1-year period two regimes of Theraﬂex it was
established effective decrease of intensity of the pain syndrome and
improvement of everyday activity in patients with knee osteoarthritis. The
analgesic effect after taking Theraﬂex becomes noticeable after three
months and quality of life signiﬁcantly improved in patients of both groups.
544 THE FLEXX TRIAL OF OSTEOARTHRITIS OF THE KNEE:
INTRA-ARTICULAR HYALURONAN (EUFLEXXATM)
R.D. Altman1, J.E. Rosen2. 1David Geffen School of Medicine at UCLA,
Los Angeles, CA, USA, 2New York University School of Medicine, New
York, NY, USA
Purpose: The FLEXX trial studied the 6 month efﬁcacy and safety of a
non-avian form of IA hyaluronan for OA of the knee.
Methods: This was a randomized, saline-controlled, double-blind study
of 586 patients with primary OA of the knee were evaluated prior to and
following 3 weekly IA injections of hyaluronan or buffered saline. The
primary efﬁcacy measurement was pain recorded for the signal knee
after a 50-foot walk. Secondary variables included the 3 subscales of the
WOMAC, OARSI responder criteria, patient global assessment, use of
rescue medication, quality of life (SF-36), and safety.
Results: The ITT population included Hyaluronan n=291 and Saline
n = 295. There were 12% dropouts (Hyaluronan n=34; Saline n = 34).
Hyaluronan demographics: Age 62.5±10.6 (SD), women 63%, BMI 32±7,
Kellgren-Lawrence grade 2−41%, grade 3−59%, initial pain 56±22 with
minimal differences from the saline group. After 26 weeks, there was a
signiﬁcant improvement in pain recorded after a 50-foot walk (ANCOVA;
p = 0.028). Secondary variables were generally supportive of the primary
measurement. Serious adverse events occurred in Hyaluronan (n = 10)
and Saline (n = 9) groups. Arthralgia occurred in Hyaluronan (n = 27)
and Saline (n = 35) groups. Local injection site reactions occurred in
Hyaluronan (n = 2) and Saline (n = 1) groups.
Conclusions: IA hyaluronan was signiﬁcantly superior to saline for OA
of the knee over a 6-month period despite a large beneﬁcial effect of IA
saline.
